RADPAD® Radiation Protection’s Post

🚨 Game-Changer for In-Stent Restenosis Treatment! 🚨 Treating in-stent restenosis (ISR) remains one of the most challenging tasks in interventional cardiology. However, a recent study published in Cardiovascular Revascularization Medicine reveals promising results using the OPN NC® Super High-Pressure Balloon in ISR treatment. With the ability to operate at pressures exceeding 30 atm, the OPN NC® balloon ensures optimal stent expansion, neointimal compression, and improved patient outcomes. In this real-world study conducted at a tertiary cardiology center, over 208 ISR lesions were treated in 188 patients with complex lesion characteristics. The OPN NC® balloon performed remarkably, showing a low rate of major complications (0.96% coronary perforation, 4% major dissections) and successful stent expansion. Furthermore, at 1-year follow-up, only 19.7% of patients experienced major adverse cardiovascular events (MACE), a testament to the balloon’s safety and efficacy. The study highlights that the OPN NC® Super High-Pressure Balloon is a critical tool for interventionalists managing complex ISR lesions, offering high confidence in challenging procedures. Contact us here on LinkedIn (RADPAD® Radiation Protection) or at our website (radpad.com) to learn more about OPN NC and to schedule an in-service training to get them on the shelf! Learn more about this groundbreaking ISR solution: https://lnkd.in/gkZcB2kv #InStentRestenosis #CardiologyInnovation #InterventionalCardiology #OPNNC #HealthcareAdvancements #PatientCare

False positive STEMI protocol activation can lead to significant and avoidable clinical and financial issues, both for the patient and for the healthcare system. Diagnostic ECG is an essential part of fast, appropriate care. #ECG #Cardiology #DCARInsights

False positive STEMI protocol activation can lead to significant and avoidable clinical and financial issues, both for the patient and for the healthcare system. Diagnostic ECG is an essential part of fast, appropriate care. #ECG #Cardiology #DCARInsights

🚀 Breakthrough in Next-Day Discharge for TAVI Procedures! 🚀 This week, ArchCath wants to spotlight a recent study published in The American Journal of Cardiology 🫀. It has emphasized the feasibility and safety of next-day discharge following transfemoral transcatheter aortic valve implantation (TAVI) using the Acurate neo/neo2 self-expanding aortic bioprosthesis. The study, conducted at the London Health Sciences Centre, Western University, evaluated 368 patients and found that next-day discharge (NDD) did not increase the risk of death or rehospitalization within 30 days post-procedure. 🔍 Key Findings Include: • 📉 Low Readmission Rates: Comparable readmission rates across patients discharged within 24 hours, 24-48 hours, and those discharged later. • 🛡️ Safety: No increase in complications for NDD patients, with a 1.4% stroke rate limited to those discharged after 48 hours. • 📈 Efficiency: NDD patients showed excellent recovery metrics without additional risk. 👆 This research is a significant step forward in optimizing TAVI procedures, improving patient outcomes, and enhancing recovery times. As we continue to innovate in the field of cardiac care, studies like this are pivotal in shaping the future of heart valve treatments. 🔗 Read the full study here: https://lnkd.in/gBvQnV73 Stay tuned with ArchCath for more exciting news and updates in the world of cardiology! 💓📈 #TAVI #Cardiology #HeartHealth #MedicalResearch #PatientCare #Innovation #Healthcare #ArchCath

False positive STEMI protocol activation can lead to significant and avoidable clinical and financial issues, both for the patient and for the healthcare system. Diagnostic ECG is an essential part of fast, appropriate care. #ECG #Cardiology #DCARInsights

During #HospitalWeek, we’re celebrating the innovative care our Heart and Vascular team provides to the community. The world's first transcatheter aortic valve replacement (TAVR) using the new, FDA-approved Evolut™ FX+ TAVR system was successfully performed right here in Pennsylvania at the UPMC Heart and Vascular Institute. This breakthrough procedure not only offers hope to patients suffering from severe aortic stenosis but also sets a new standard in cardiac procedures. The patient, an 82-year-old woman from Elliottsburg, Pa. with aortic valve stenosis, was the first person in the world to undergo this new type of transcatheter aortic valve replacement and has been discharged and is recovering well. Hemal Gada, MD, president, UPMC Heart and Vascular Institute in Central Pa. performed the procedure using the newest-generation FDA approved Evolut™ FX+ TAVR system for the treatment of symptomatic severe aortic stenosis. Dr. Gada is the first interventional cardiologist in the world to use this latest Evolut FX+ TAVR system. "This is a significant achievement for patient care in our region," said Gada. "The primary distinguishing feature of the Evolut FX+ and the previous Evolut system is the ease of accessing the coronary arteries, facilitated by the large openings in the valve frame. This system's improved lifetime management is highly beneficial to patients undergoing the TAVR procedure, especially younger patients who may require additional procedures in the future.” The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform but allows larger coronary access windows through a modified diamond-shaped frame design, which is four times larger than previous iterations of the Evolut TAVR system. Evolut FX+ provides increased space for catheter maneuverability to facilitate access to coronary arteries of varying patient anatomies.

False positive STEMI protocol activation can lead to significant and avoidable clinical and financial issues, both for the patient and for the healthcare system. Diagnostic ECG is an essential part of fast, appropriate care. #ECG #Cardiology #DCARInsights

False positive STEMI protocol activation can lead to significant and avoidable clinical and financial issues, both for the patient and for the healthcare system. Diagnostic ECG is an essential part of fast, appropriate care. #ECG #Cardiology #DCARInsights

🌟 ArchCath has spotlighted a groundbreaking study from The American Journal of Cardiology, which shed light on the safety and feasibility of next-day discharge for patients undergoing TAVI procedures. Conducted at the London Health Sciences Centre, this study evaluated 368 patients and found that discharging patients the day after their procedure didn't increase the risk of death or rehospitalization within 30 days. These findings could revolutionize patient recovery times and hospital efficiency, highlighting significant improvements in cardiac care. Curious to learn more about these innovative results? Dive into the post to see how this research is paving the way for better heart health outcomes! 💓 #Cardiology #HeartHealth #CardiacCare #PatientCare #MedicalResearch #TAVI #HealthTech #Innovation #HealthcareInnovation #ArchCath 

False positive STEMI protocol activation can lead to significant and avoidable clinical and financial issues, both for the patient and for the healthcare system. Diagnostic ECG is an essential part of fast, appropriate care. #ECG #Cardiology #DCARInsights